277 related articles for article (PubMed ID: 21307639)
1. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS
Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639
[TBL] [Abstract][Full Text] [Related]
2. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
[TBL] [Abstract][Full Text] [Related]
3. Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer.
Antoon JW; White MD; Driver JL; Burow ME; Beckman BS
Exp Biol Med (Maywood); 2012 Jul; 237(7):832-44. PubMed ID: 22859737
[TBL] [Abstract][Full Text] [Related]
4. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
[TBL] [Abstract][Full Text] [Related]
5. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.
White MD; Chan L; Antoon JW; Beckman BS
Anticancer Res; 2013 Sep; 33(9):3573-9. PubMed ID: 24023282
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
Guan S; Liu YY; Yan T; Zhou J
Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
[TBL] [Abstract][Full Text] [Related]
7. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.
Antoon JW; White MD; Meacham WD; Slaughter EM; Muir SE; Elliott S; Rhodes LV; Ashe HB; Wiese TE; Smith CD; Burow ME; Beckman BS
Endocrinology; 2010 Nov; 151(11):5124-35. PubMed ID: 20861237
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression.
Hasanifard L; Samadi N; Rashtchizadeh N; Dastmalchi S; Karimi P
Drug Res (Stuttg); 2018 Jan; 68(1):45-53. PubMed ID: 28950390
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival.
Gestaut MM; Antoon JW; Burow ME; Beckman BS
Pharmacol Rep; 2014 Feb; 66(1):174-8. PubMed ID: 24905325
[TBL] [Abstract][Full Text] [Related]
13. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
Zhou J; Chen J; Yu H
Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
[TBL] [Abstract][Full Text] [Related]
14. A novel sphingosine kinase inhibitor induces autophagy in tumor cells.
Beljanski V; Knaak C; Smith CD
J Pharmacol Exp Ther; 2010 May; 333(2):454-64. PubMed ID: 20179157
[TBL] [Abstract][Full Text] [Related]
15. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
[TBL] [Abstract][Full Text] [Related]
16. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.
Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C
Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858
[TBL] [Abstract][Full Text] [Related]
17. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.
Qin Z; Dai L; Trillo-Tinoco J; Senkal C; Wang W; Reske T; Bonstaff K; Del Valle L; Rodriguez P; Flemington E; Voelkel-Johnson C; Smith CD; Ogretmen B; Parsons C
Mol Cancer Ther; 2014 Jan; 13(1):154-64. PubMed ID: 24140934
[TBL] [Abstract][Full Text] [Related]
18. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.
Dai L; Smith CD; Foroozesh M; Miele L; Qin Z
Int J Cancer; 2018 May; 142(10):2153-2162. PubMed ID: 29277894
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
Beljanski V; Lewis CS; Smith CD
Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.
LeBlanc FR; Pearson JM; Tan SF; Cheon H; Xing JC; Dunton W; Feith DJ; Loughran TP
Br J Haematol; 2020 Aug; 190(3):405-417. PubMed ID: 32124438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]